Skip to main content
Premium Trial:

Request an Annual Quote

Acceler8 Reports Big Revenue Jump in Q2 2005

NEW YORK, March 17 (GenomeWeb News) - Acceler8's second-quarter fiscal 2005 net revenues jumped 654 percent to $241,946, from $36,968 in the same quarter in the previous year, the company said today.


The company's net loss narrowed from $474,341, or $.04 per share, in the second quarter of 2005 to $359,527, or $.03 per share, the company said.


"We expect to have the first research version [of Acceler8's Baccelr8r bacterial analyzer and monitoring system] early in calendar 2006," said David Howson, Accelr8 president.


Accelr8 did not break out its R&D spend or its cash on hand in its statement.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.